首页 > 最新文献

Acupuncture and herbal medicine最新文献

英文 中文
An umbrella review of Lianhua Qingwen combined with Western medicine for the treatment of coronavirus disease 2019. 莲花清瘟联合西药治疗2019冠状病毒病的综述。
Pub Date : 2022-09-01 Epub Date: 2022-12-08 DOI: 10.1097/HM9.0000000000000041
Kelu Yang, Jiaoyan Zhang, Liang Zhao, Luying Cheng, Yuanyuan Li, Yuchen Kang, Xiangyu Zhang, Yingying Kang

Lianhua Qingwen combined with Western medicine (LHQW+WM) has been proposed as a viable treatment for coronavirus disease 2019 (COVID-19). Interestingly, umbrella reviews of systematic reviews (SRs), which provide the most comprehensive evidence, are the best evidence in evidence-based medicine. Therefore, an umbrella review of SRs that summarizes and evaluates the efficacy of LHQW+WM for COVID-19 is urgently required.

Methods: Overall, 6 databases were used to conduct a comprehensive literature search from inception to January 22, 2022. The corrected covered area (CCA) was used to analyze the overlapping between SRs. Meta-analysis was conducted when that of the included SRs was inappropriate. A MeaSurement Tool to Assess Systematic Reviews (AMSTAR-2) was also employed to assess the quality of the included SRs.

Results: In total, 12 SRs were identified, which included 12 unique primary studies. The included SRs ranged in quality from moderate to critically low and had an extremely high CCA (36.4%). Compared to conventional treatment, LHQW+WM showed efficacy concerning fatigue recovery [risk ratio (RR) = 1.69, 95% confidence interval (CI): 1.04-2.73, n = 2, I2 = 0%], cough recovery (RR = 1.65, 95% CI: 1.09-2.51, n = 3, I2 = 39.1%), and overall effective rates (RR = 1.17, 95% CI: 1.07-1.28, n = 3, I2 = 17.5%).

Conclusion: LHQW+WM may improve the clinical symptoms of patients with COVID-19; however, the results should be interpreted cautiously because of the rigorous processes in the included SRs.

Graphical abstract: http://links.lww.com/AHM/A32.

莲花清温联合西药(LHQW+WM)被认为是2019冠状病毒病(新冠肺炎)的一种可行的治疗方法。有趣的是,系统综述的总括综述提供了最全面的证据,是循证医学中最好的证据。因此,迫切需要对SR进行全面审查,总结和评估LHQW+WM治疗新冠肺炎的疗效。方法:从成立到2022年1月22日,共使用6个数据库进行全面的文献检索。校正覆盖面积(CCA)用于分析SR之间的重叠。当纳入的SRs的荟萃分析不合适时,进行荟萃分析。评估系统评价的测量工具(AMSTAR-2)也被用于评估纳入的SR的质量。结果:总共确定了12个SR,其中包括12个独特的初级研究。纳入的SR质量从中度到极低不等,具有极高的CCA(36.4%)。与传统治疗相比,LHQW+WM在疲劳恢复[风险比(RR)=1.69,95%置信区间(CI):1.04-2.73,n=2,I2=0%]、咳嗽恢复(RR=1.65,95%CI:1.09-2.51,n=3,I2=39.1%)方面表现出疗效,总有效率(RR=1.17,95%CI:1.07-1.28,n=3,I2=17.5%)。结论:LHQW+WM可改善新冠肺炎患者的临床症状;然而,由于包含的SR中有严格的过程,因此应谨慎解释结果。图形摘要:http://links.lww.com/AHM/A32.
{"title":"An umbrella review of Lianhua Qingwen combined with Western medicine for the treatment of coronavirus disease 2019.","authors":"Kelu Yang, Jiaoyan Zhang, Liang Zhao, Luying Cheng, Yuanyuan Li, Yuchen Kang, Xiangyu Zhang, Yingying Kang","doi":"10.1097/HM9.0000000000000041","DOIUrl":"10.1097/HM9.0000000000000041","url":null,"abstract":"<p><p>Lianhua Qingwen combined with Western medicine (LHQW+WM) has been proposed as a viable treatment for coronavirus disease 2019 (COVID-19). Interestingly, umbrella reviews of systematic reviews (SRs), which provide the most comprehensive evidence, are the best evidence in evidence-based medicine. Therefore, an umbrella review of SRs that summarizes and evaluates the efficacy of LHQW+WM for COVID-19 is urgently required.</p><p><strong>Methods: </strong>Overall, 6 databases were used to conduct a comprehensive literature search from inception to January 22, 2022. The corrected covered area (CCA) was used to analyze the overlapping between SRs. Meta-analysis was conducted when that of the included SRs was inappropriate. A MeaSurement Tool to Assess Systematic Reviews (AMSTAR-2) was also employed to assess the quality of the included SRs.</p><p><strong>Results: </strong>In total, 12 SRs were identified, which included 12 unique primary studies. The included SRs ranged in quality from moderate to critically low and had an extremely high CCA (36.4%). Compared to conventional treatment, LHQW+WM showed efficacy concerning fatigue recovery [risk ratio (<i>RR</i>) = 1.69, 95% confidence interval (<i>CI</i>): 1.04-2.73, <i>n</i> = 2, <i>I</i><sup>2</sup> = 0%], cough recovery (<i>RR</i> = 1.65, 95% <i>CI</i>: 1.09-2.51, <i>n</i> = 3, <i>I</i><sup>2</sup> = 39.1%), and overall effective rates (<i>RR</i> = 1.17, 95% <i>CI</i>: 1.07-1.28, <i>n</i> = 3, <i>I</i><sup>2</sup> = 17.5%).</p><p><strong>Conclusion: </strong>LHQW+WM may improve the clinical symptoms of patients with COVID-19; however, the results should be interpreted cautiously because of the rigorous processes in the included SRs.</p><p><strong>Graphical abstract: </strong>http://links.lww.com/AHM/A32.</p>","PeriodicalId":93856,"journal":{"name":"Acupuncture and herbal medicine","volume":"2 3","pages":"143-151"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/86/hm9-2-143.PMC9746252.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41164621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regulation of innate and adaptive immunity using herbal medicine: benefits for the COVID-19 vaccination. 使用草药调节先天免疫和适应性免疫:对新冠肺炎疫苗接种的益处。
Pub Date : 2022-09-01 Epub Date: 2022-12-08 DOI: 10.1097/HM9.0000000000000046
Xuan Li, Nuttapong Wichai, Jiabao Wang, Xiuping Liu, Huimin Yan, Yu Wang, Mingchi Luo, Shengyuan Zhou, Kai Wang, Lin Li, Lin Miao

Vaccination is a major achievement that has become an effective prevention strategy against infectious diseases and active control of emerging pathogens worldwide. In response to the coronavirus disease 2019 (COVID-19) pandemic, several diverse vaccines against severe acute respiratory syndrome coronavirus 2 have been developed and deployed for use in a large number of individuals, and have been reported to protect against symptomatic COVID-19 cases and deaths. However, the application of vaccines has a series of limitations, including protective failure for variants of concern, unavailability of individuals due to immune deficiency, and the disappearance of immune protection for increasing infections in vaccinated individuals. These aspects raise the question of how to modulate the immune system that contributes to the COVID-19 vaccine protective effects. Herbal medicines are widely used for their immune regulatory abilities in clinics. More attractively, herbal medicines have been well accepted for their positive role in the COVID-19 prevention and suppression through regulation of the immune system. This review presents a brief overview of the strategy of COVID-19 vaccination and the response of the immune system to vaccines, the regulatory effects and mechanisms of herbal medicine in immune-related macrophages, natural killer cells, dendritic cells, and lymphocytes T and B cells, and how they help vaccines work. Later in the article, the potential role and application of herbal medicines in the most recent COVID-19 vaccination are discussed. This article provides new insights into herbal medicines as promising alternative supplements that may benefit from COVID-19 vaccination.

Graphical abstract: http://links.lww.com/AHM/A31.

疫苗接种是一项重大成就,已成为全球范围内有效预防传染病和积极控制新发病原体的战略。为了应对2019冠状病毒病(新冠肺炎)大流行,已经开发并部署了几种针对严重急性呼吸综合征冠状病毒2的不同疫苗,用于大量个人,据报道,这些疫苗可以预防有症状的新冠肺炎病例和死亡。然而,疫苗的应用有一系列局限性,包括对变异毒株的保护失败、因免疫缺陷而无法获得个体,以及对接种疫苗的个体感染增加的免疫保护消失。这些方面提出了如何调节有助于新冠肺炎疫苗保护作用的免疫系统的问题。草药因其免疫调节能力而被广泛应用于临床。更具吸引力的是,草药因其通过调节免疫系统在预防和抑制新冠肺炎方面的积极作用而广为接受。这篇综述简要概述了新冠肺炎疫苗接种策略和免疫系统对疫苗的反应,草药对免疫相关巨噬细胞、自然杀伤细胞、树突状细胞、淋巴细胞T和B细胞的调节作用和机制,以及它们如何帮助疫苗发挥作用。文章后面讨论了草药在最近新冠肺炎疫苗接种中的潜在作用和应用。这篇文章为草药作为可能受益于新冠肺炎疫苗接种的有前景的替代补充剂提供了新的见解。图形摘要:http://links.lww.com/AHM/A31.
{"title":"Regulation of innate and adaptive immunity using herbal medicine: benefits for the COVID-19 vaccination.","authors":"Xuan Li,&nbsp;Nuttapong Wichai,&nbsp;Jiabao Wang,&nbsp;Xiuping Liu,&nbsp;Huimin Yan,&nbsp;Yu Wang,&nbsp;Mingchi Luo,&nbsp;Shengyuan Zhou,&nbsp;Kai Wang,&nbsp;Lin Li,&nbsp;Lin Miao","doi":"10.1097/HM9.0000000000000046","DOIUrl":"10.1097/HM9.0000000000000046","url":null,"abstract":"<p><p>Vaccination is a major achievement that has become an effective prevention strategy against infectious diseases and active control of emerging pathogens worldwide. In response to the coronavirus disease 2019 (COVID-19) pandemic, several diverse vaccines against severe acute respiratory syndrome coronavirus 2 have been developed and deployed for use in a large number of individuals, and have been reported to protect against symptomatic COVID-19 cases and deaths. However, the application of vaccines has a series of limitations, including protective failure for variants of concern, unavailability of individuals due to immune deficiency, and the disappearance of immune protection for increasing infections in vaccinated individuals. These aspects raise the question of how to modulate the immune system that contributes to the COVID-19 vaccine protective effects. Herbal medicines are widely used for their immune regulatory abilities in clinics. More attractively, herbal medicines have been well accepted for their positive role in the COVID-19 prevention and suppression through regulation of the immune system. This review presents a brief overview of the strategy of COVID-19 vaccination and the response of the immune system to vaccines, the regulatory effects and mechanisms of herbal medicine in immune-related macrophages, natural killer cells, dendritic cells, and lymphocytes T and B cells, and how they help vaccines work. Later in the article, the potential role and application of herbal medicines in the most recent COVID-19 vaccination are discussed. This article provides new insights into herbal medicines as promising alternative supplements that may benefit from COVID-19 vaccination.</p><p><strong>Graphical abstract: </strong>http://links.lww.com/AHM/A31.</p>","PeriodicalId":93856,"journal":{"name":"Acupuncture and herbal medicine","volume":"2 3","pages":"196-206"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b6/41/hm9-2-196.PMC9746255.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41165148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Herbal medicine in the treatment of COVID-19 based on the gut-lung axis. 中药治疗新冠肺炎基于骨肺轴。
Pub Date : 2022-09-01 Epub Date: 2022-12-08 DOI: 10.1097/HM9.0000000000000038
Qiaoyu He, Yumeng Shi, Qian Tang, Hong Xing, Han Zhang, Mei Wang, Xiaopeng Chen

Respiratory symptoms are most commonly experienced by patients in the early stages of novel coronavirus disease 2019 (COVID-19). However, with a better understanding of COVID-19, gastrointestinal symptoms such as diarrhea, nausea, and vomiting have attracted increasing attention. The gastrointestinal tract may be a target organ of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The intestinal microecological balance is a crucial factor for homeostasis, including immunity and inflammation, which are closely related to COVID-19. Herbal medicine can restore intestinal function and regulate the gut flora structure. Herbal medicine has a long history of treating lung diseases from the perspective of the intestine, which is called the gut-lung axis. The physiological activities of guts and lungs influence each other through intestinal flora, microflora metabolites, and mucosal immunity. Microecological modulators are included in the diagnosis and treatment protocols for COVID-19. In this review, we demonstrate the relationship between COVID-19 and the gut, gut-lung axis, and the role of herbal medicine in treating respiratory diseases originating from the intestinal tract. It is expected that the significance of herbal medicine in treating respiratory diseases from the perspective of the intestinal tract could lead to new ideas and methods for treatment.

Graphical abstract: http://links.lww.com/AHM/A33.

呼吸道症状最常见于2019年新型冠状病毒疾病(新冠肺炎)早期患者。然而,随着对新冠肺炎的进一步了解,腹泻、恶心和呕吐等胃肠道症状引起了越来越多的关注。胃肠道可能是严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)感染的靶器官。肠道微生态平衡是体内平衡的关键因素,包括与新冠肺炎密切相关的免疫和炎症。草药可以恢复肠道功能,调节肠道菌群结构。草药从肠道的角度治疗肺部疾病有着悠久的历史,肠道被称为肠肺轴。肠道和肺部的生理活动通过肠道菌群、微生物代谢产物和粘膜免疫相互影响。微生态调节剂被纳入新冠肺炎的诊断和治疗方案。在这篇综述中,我们展示了新冠肺炎与肠道、骨肺轴之间的关系,以及草药在治疗源自肠道的呼吸道疾病中的作用。从肠道的角度来看,草药治疗呼吸道疾病的意义有望带来新的治疗思路和方法。图形摘要:http://links.lww.com/AHM/A33.
{"title":"Herbal medicine in the treatment of COVID-19 based on the gut-lung axis.","authors":"Qiaoyu He,&nbsp;Yumeng Shi,&nbsp;Qian Tang,&nbsp;Hong Xing,&nbsp;Han Zhang,&nbsp;Mei Wang,&nbsp;Xiaopeng Chen","doi":"10.1097/HM9.0000000000000038","DOIUrl":"10.1097/HM9.0000000000000038","url":null,"abstract":"<p><p>Respiratory symptoms are most commonly experienced by patients in the early stages of novel coronavirus disease 2019 (COVID-19). However, with a better understanding of COVID-19, gastrointestinal symptoms such as diarrhea, nausea, and vomiting have attracted increasing attention. The gastrointestinal tract may be a target organ of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The intestinal microecological balance is a crucial factor for homeostasis, including immunity and inflammation, which are closely related to COVID-19. Herbal medicine can restore intestinal function and regulate the gut flora structure. Herbal medicine has a long history of treating lung diseases from the perspective of the intestine, which is called the gut-lung axis. The physiological activities of guts and lungs influence each other through intestinal flora, microflora metabolites, and mucosal immunity. Microecological modulators are included in the diagnosis and treatment protocols for COVID-19. In this review, we demonstrate the relationship between COVID-19 and the gut, gut-lung axis, and the role of herbal medicine in treating respiratory diseases originating from the intestinal tract. It is expected that the significance of herbal medicine in treating respiratory diseases from the perspective of the intestinal tract could lead to new ideas and methods for treatment.</p><p><strong>Graphical abstract: </strong>http://links.lww.com/AHM/A33.</p>","PeriodicalId":93856,"journal":{"name":"Acupuncture and herbal medicine","volume":"2 3","pages":"172-183"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/81/hm9-2-172.PMC9746256.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41160160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Post COVID-19 burden: focus on the short-term condition. 新冠肺炎后的负担:关注短期状况。
Pub Date : 2022-09-01 Epub Date: 2022-12-08 DOI: 10.1097/HM9.0000000000000036
Fengwen Yang, Bo Pang, Xinyao Jin, Zhe Chen, Wentai Pang, Qingquan Liu, Junhua Zhang, Boli Zhang
The catastrophic pandemic of the coronavirus disease 2019 (COVID-19) has caused serious harm to human life and global social economy. As of June 13, 2022, there were more than 530 million confirmed cases of COVID19 and over 6.3 million deaths[1]. During the past 2 years, global studies on prevention and therapies for COVID19 have achieved a series of promising findings, including antiviral drugs (Remdesivir, Molnupiravir, Paxlovid) and monoclonal antibodies (Bamlanivimab and Etesevimab, Sotrovimab, Casirivimab and Imdevimab)[2]. World Health Organization (WHO) has validated 11 vaccines for the emergency use listing (EUL)[3]. As of June 13, 2022, more than 11.9 billion vaccine doses have been administered worldwide[1]. In China, integrated using of traditional Chinese medicine (TCM) and Western medicine is one of the highlights in fighting COVID-19. “Three formulations and three drugs” (Jinhua Qinggan granules, Lianhua Qingwen capsule, Xuebijing injection, and Qingfei Paidu decoction, Huashi Baidu decoction, Xuanfei Baidu decoction) have been approved by National Medical Products Administration (NMPA) as new drugs or adding indications for COVID-19[4]. The new drugs and vaccines had become effective weapons in the fight against the pandemic.
{"title":"Post COVID-19 burden: focus on the short-term condition.","authors":"Fengwen Yang,&nbsp;Bo Pang,&nbsp;Xinyao Jin,&nbsp;Zhe Chen,&nbsp;Wentai Pang,&nbsp;Qingquan Liu,&nbsp;Junhua Zhang,&nbsp;Boli Zhang","doi":"10.1097/HM9.0000000000000036","DOIUrl":"10.1097/HM9.0000000000000036","url":null,"abstract":"The catastrophic pandemic of the coronavirus disease 2019 (COVID-19) has caused serious harm to human life and global social economy. As of June 13, 2022, there were more than 530 million confirmed cases of COVID19 and over 6.3 million deaths[1]. During the past 2 years, global studies on prevention and therapies for COVID19 have achieved a series of promising findings, including antiviral drugs (Remdesivir, Molnupiravir, Paxlovid) and monoclonal antibodies (Bamlanivimab and Etesevimab, Sotrovimab, Casirivimab and Imdevimab)[2]. World Health Organization (WHO) has validated 11 vaccines for the emergency use listing (EUL)[3]. As of June 13, 2022, more than 11.9 billion vaccine doses have been administered worldwide[1]. In China, integrated using of traditional Chinese medicine (TCM) and Western medicine is one of the highlights in fighting COVID-19. “Three formulations and three drugs” (Jinhua Qinggan granules, Lianhua Qingwen capsule, Xuebijing injection, and Qingfei Paidu decoction, Huashi Baidu decoction, Xuanfei Baidu decoction) have been approved by National Medical Products Administration (NMPA) as new drugs or adding indications for COVID-19[4]. The new drugs and vaccines had become effective weapons in the fight against the pandemic.","PeriodicalId":93856,"journal":{"name":"Acupuncture and herbal medicine","volume":"2 3","pages":"139-142"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d6/be/hm9-2-139.PMC9746249.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41159332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Symptoms associated with nucleic acid turning-negative-time in COVID-19 patients? 新冠肺炎患者核酸转阴时间相关症状?
Pub Date : 2022-09-01 Epub Date: 2022-12-08 DOI: 10.1097/HM9.0000000000000037
Qiang Li, Lei Zhang, Limin Feng, Hongyuan Sun, Yan Ma, Xiaoya Liu, Cunzhong Shi, Mingchi Luo
Objective: To explore on the association between nucleic acid turning-negative-time and traditional Chinese medicine (TCM) symptoms in coronavirus disease 2019 (COVID-19) patients with the Omicron variant. Method: For this retrospective cross-sectional study, we enrolled 189 patients with COVID-19 (age 20–90 years) were included. multiple linear regression models were used to investigate the TCM symptoms affecting the nucleic acid turning-negative-time of COVID-19 patients, during the process of data analysis, taking with nucleic acid turning-negative-time as the dependent variable, and TCM symptoms as independent variables, and at the same time, sex, age, hypertension, diabetes, and coronary heart disease were as confounding variables. Results: The study found that the most common TCM symptoms of COVID-19 patients with Omicron were cough, dry throat, expectoration, fever, sore throat, pharyngeal itching, running nose, and nasal congestion. Regression analysis showed that the fit regressive equation showed a significant difference (F = 4.286, P < 0.001), R = 0.400, the adjusted R 2 = 0.123, and three variables in the regression equation showed significant difference (P < 0. 05). The results showed that nucleic acid turning-negative-time was mostly related to constipation, fever, and expectoration. If the patients had the symptoms of constipation, fever, and expectoration; that is, if patients showed these symptoms, the turning-negative-time of nucleic acid in patients with Omicron will be prolonged. Conclusions: Treatment based on symptoms for patients with constipation, fever, and expectoration may have important clinical significance for the COVID-19 patients with Omicron.
探讨2019冠状病毒病(新冠肺炎)奥密克戎变异株患者核酸转阴时间与中医症状的关系。方法:在这项回顾性横断面研究中,我们纳入了189名新冠肺炎患者(年龄20-90岁)。采用多元线性回归模型,以新冠肺炎患者核酸转阴时间为因变量,以中医症状为自变量,同时以性别、年龄、高血压、糖尿病、,冠心病是混淆变量。结果:研究发现,新冠肺炎奥密克戎患者最常见的中医症状是咳嗽、喉咙干、咳痰、发烧、喉咙痛、咽痒、流鼻涕和鼻塞。回归分析表明,拟合回归方程显示出显著差异(F=4.286,P<0.001),R=0.400,调整后的R 2=0.123,回归方程中三个变量差异有统计学意义(P<0.05)。05)。结果表明,核酸转阴时间主要与便秘、发热、咳痰有关。患者是否有便秘、发热、咳痰等症状;也就是说,如果患者出现这些症状,奥密克戎患者的核酸转阴时间将延长。结论:对新冠肺炎奥密克戎患者,根据症状治疗便秘、发热和咳痰可能具有重要的临床意义。
{"title":"Symptoms associated with nucleic acid turning-negative-time in COVID-19 patients?","authors":"Qiang Li,&nbsp;Lei Zhang,&nbsp;Limin Feng,&nbsp;Hongyuan Sun,&nbsp;Yan Ma,&nbsp;Xiaoya Liu,&nbsp;Cunzhong Shi,&nbsp;Mingchi Luo","doi":"10.1097/HM9.0000000000000037","DOIUrl":"10.1097/HM9.0000000000000037","url":null,"abstract":"Objective: To explore on the association between nucleic acid turning-negative-time and traditional Chinese medicine (TCM) symptoms in coronavirus disease 2019 (COVID-19) patients with the Omicron variant. Method: For this retrospective cross-sectional study, we enrolled 189 patients with COVID-19 (age 20–90 years) were included. multiple linear regression models were used to investigate the TCM symptoms affecting the nucleic acid turning-negative-time of COVID-19 patients, during the process of data analysis, taking with nucleic acid turning-negative-time as the dependent variable, and TCM symptoms as independent variables, and at the same time, sex, age, hypertension, diabetes, and coronary heart disease were as confounding variables. Results: The study found that the most common TCM symptoms of COVID-19 patients with Omicron were cough, dry throat, expectoration, fever, sore throat, pharyngeal itching, running nose, and nasal congestion. Regression analysis showed that the fit regressive equation showed a significant difference (F = 4.286, P < 0.001), R = 0.400, the adjusted R 2 = 0.123, and three variables in the regression equation showed significant difference (P < 0. 05). The results showed that nucleic acid turning-negative-time was mostly related to constipation, fever, and expectoration. If the patients had the symptoms of constipation, fever, and expectoration; that is, if patients showed these symptoms, the turning-negative-time of nucleic acid in patients with Omicron will be prolonged. Conclusions: Treatment based on symptoms for patients with constipation, fever, and expectoration may have important clinical significance for the COVID-19 patients with Omicron.","PeriodicalId":93856,"journal":{"name":"Acupuncture and herbal medicine","volume":"2 3","pages":"207-209"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/5f/hm9-2-207.PMC9746246.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41170049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Traditional Chinese medicine for promoting mental health of patients with COVID-19: a scoping review. 中医药促进新冠肺炎患者心理健康:范围界定综述。
Pub Date : 2022-09-01 Epub Date: 2022-12-08 DOI: 10.1097/HM9.0000000000000045
Zhaochen Ji, Haiyin Hu, Danlei Wang, Marco Di Nitto, Alice Josephine Fauci, Masayoshi Okada, Kai Li, Hui Wang

This study aimed to systematically review and depict the current studies of traditional Chinese medicine for the mental health of patients with coronavirus disease 2019 (COVID-19).

Methods: A scoping review was conducted by searching PubMed, Web of Science, CNKI, Wanfang database, VIP database, and SinoMed, with the retrieval time being from the establishment of the database to April 18, 2022. The basic information of the included studies, objective, design, types of patients, interventions, outcomes, etc., was reviewed and summarized narratively. Methodological quality was assessed using the Cochrane Risk of Bias assessment tool, the methodological index for non-randomized studies or the Newcastle-Ottawa scale.

Results: We identified 30 traditional Chinese medicine (TCM) studies from six databases. Among them, finished randomized controlled trials (n = 16) accounted for most of the studies, followed by single-arm studies (n = 9). In terms of study theme, 20 studies defined the mental health of patients with COVID-19 as the research theme. Psychological assessment was included in the inclusion criteria (performed before participation) of nine studies, whereas the other studies only mentioned the mental outcomes. TCM interventions included TCM exercises (Yijinjing, Baduanjin, Liuzijue, Taichi), acupoint stimulation (auricular and body points), moxibustion, decoction, or granules based on TCM syndrome differentiation, decoction, or granules with fixed formulae (Baidu Jieduan granules, Xuanfei Baidu decoction, and Qingfei Paidu decoction), Chinese patent medicine (Jinhua Qinggan granules), TCM psychological therapy (TCM ideological therapy, TCM five-tone therapy, and TCM psychological sand table), and TCM nursing (dialectical care, dialectical diet, and psychological counseling). Anxiety and depression were the main outcomes evaluated in regard to mental health in patients with COVID-19. The limitations of methodological quality were predominantly from follow-up, blinding, and registration. Positive results were reported by 27 studies (90%, n = 30).

Conclusion: We summarized the existing literature about the impact of TCM on mental health in patients with COVID-19. The number of studies evaluating the impact of TCM on mental health is encouraging, but overall methodological quality was low. Several TCM interventions warrant further evaluation, particularly among populations outside of China, for the purpose of establishing supporting evidence. More importantly, research with stronger methodological quality needs to be developed.

Graphical abstract: http://links.lww.com/AHM/A36.

本研究旨在系统回顾和描述中医药对2019冠状病毒病(新冠肺炎)患者心理健康的研究现状。方法:检索PubMed、Web of Science、CNKI、万方数据库、VIP数据库和SinoMed,检索时间从数据库建立到2022年4月18日。对纳入的研究的基本信息、目的、设计、患者类型、干预措施、结果等进行了回顾和叙述性总结。方法学质量使用Cochrane偏倚风险评估工具、非随机研究的方法学指数或Newcastle Ottawa量表进行评估。结果:我们从6个数据库中确定了30项中药研究。其中,完成的随机对照试验(n=16)占大多数研究,其次是单臂研究(n=9)。在研究主题方面,20项研究将新冠肺炎患者的心理健康定义为研究主题。心理评估被纳入了九项研究的纳入标准(在参与之前进行),而其他研究只提到了心理结果。中医干预包括中医运动(易筋经、八段锦、六子觉、太极)、穴位刺激(耳穴、体穴)、艾灸、煎液、辨证颗粒、煎液或定方颗粒(百度解毒颗粒、宣肺败毒汤、清肺排毒汤)、中成药(金花清肝颗粒)、,中医心理治疗(中医思想治疗、中医五音治疗、中医心理沙盘)、中医护理(辩证护理、辩证饮食、心理疏导)。在新冠肺炎患者的心理健康方面,焦虑和抑郁是评估的主要结果。方法学质量的局限性主要来自随访、盲法和登记。27项研究报告了阳性结果(90%,n=30)。结论:我们总结了现有关于中医药对新冠肺炎患者心理健康影响的文献。评估中医药对心理健康影响的研究数量令人鼓舞,但总体方法质量较低。一些中医干预措施值得进一步评估,特别是在中国以外的人群中,以建立支持性证据。更重要的是,需要开展方法论质量更强的研究。图形摘要:http://links.lww.com/AHM/A36.
{"title":"Traditional Chinese medicine for promoting mental health of patients with COVID-19: a scoping review.","authors":"Zhaochen Ji, Haiyin Hu, Danlei Wang, Marco Di Nitto, Alice Josephine Fauci, Masayoshi Okada, Kai Li, Hui Wang","doi":"10.1097/HM9.0000000000000045","DOIUrl":"10.1097/HM9.0000000000000045","url":null,"abstract":"<p><p>This study aimed to systematically review and depict the current studies of traditional Chinese medicine for the mental health of patients with coronavirus disease 2019 (COVID-19).</p><p><strong>Methods: </strong>A scoping review was conducted by searching PubMed, Web of Science, CNKI, Wanfang database, VIP database, and SinoMed, with the retrieval time being from the establishment of the database to April 18, 2022. The basic information of the included studies, objective, design, types of patients, interventions, outcomes, etc., was reviewed and summarized narratively. Methodological quality was assessed using the Cochrane Risk of Bias assessment tool, the methodological index for non-randomized studies or the Newcastle-Ottawa scale.</p><p><strong>Results: </strong>We identified 30 traditional Chinese medicine (TCM) studies from six databases. Among them, finished randomized controlled trials (<i>n</i> = 16) accounted for most of the studies, followed by single-arm studies (n = 9). In terms of study theme, 20 studies defined the mental health of patients with COVID-19 as the research theme. Psychological assessment was included in the inclusion criteria (performed before participation) of nine studies, whereas the other studies only mentioned the mental outcomes. TCM interventions included TCM exercises (Yijinjing, Baduanjin, Liuzijue, Taichi), acupoint stimulation (auricular and body points), moxibustion, decoction, or granules based on TCM syndrome differentiation, decoction, or granules with fixed formulae (Baidu Jieduan granules, Xuanfei Baidu decoction, and Qingfei Paidu decoction), Chinese patent medicine (Jinhua Qinggan granules), TCM psychological therapy (TCM ideological therapy, TCM five-tone therapy, and TCM psychological sand table), and TCM nursing (dialectical care, dialectical diet, and psychological counseling). Anxiety and depression were the main outcomes evaluated in regard to mental health in patients with COVID-19. The limitations of methodological quality were predominantly from follow-up, blinding, and registration. Positive results were reported by 27 studies (90%, <i>n</i> = 30).</p><p><strong>Conclusion: </strong>We summarized the existing literature about the impact of TCM on mental health in patients with COVID-19. The number of studies evaluating the impact of TCM on mental health is encouraging, but overall methodological quality was low. Several TCM interventions warrant further evaluation, particularly among populations outside of China, for the purpose of establishing supporting evidence. More importantly, research with stronger methodological quality needs to be developed.</p><p><strong>Graphical abstract: </strong>http://links.lww.com/AHM/A36.</p>","PeriodicalId":93856,"journal":{"name":"Acupuncture and herbal medicine","volume":"2 3","pages":"184-195"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/30/1e/hm9-2-184.PMC9746253.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41176195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Moxibustion for COVID-19: a systematic scoping review. 艾灸治疗新冠肺炎:一项系统的范围界定综述。
Pub Date : 2022-09-01 Epub Date: 2022-12-08 DOI: 10.1097/HM9.0000000000000044
Meng Xia, Bo Pang, Shaowei Yi, Xinjue Shan, Shizhe Deng, Yinan Qin, Tao Jiang, Hai Lu

Moxibustion has been widely used in the prevention and treatment of COVID-19. However, there is no systematic review of current topics and clinical findings on moxibustion for COVID-19. We conducted this scoping review to systematically summarize and analyze the themes and findings of published articles, and to provide an overview of current knowledge and practice of moxibustion for COVID-19.

Methods: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, SinoMed, Wan Fang Data, and VIP databases were searched from inception until April 2022. The relevant data were presented through bar graphs, structured tables, and figures along with descriptive statistics and analysis. This scoping review was conducted based on the PRISMA-ScR Checklist.

Results: A total of 76 articles were reviewed: 47 reviews, 19 clinical research studies, seven systematic reviews (all were protocols), and three guidelines. All the studies were conducted by Chinese researchers and published from January 1, 2020 to March 14, 2022. The feasibility of moxibustion in the prevention and treatment of mild or moderate COVID-19 is based on the consensus of therapeutic mechanisms and effectiveness. The most adopted approach was the suspended and gentle moxibustion, and the most frequently applied or recommended acupoints were found to be ST36, CV8, CV6, CV4, CV12, GV14, BL13, LI4, ST25, and LR3.

Conclusions: As a convenient and safe traditional Chinese medicine (TCM) therapy with its specific feature, moxibustion has been significantly effective at ameliorating mild or moderate symptoms among COVID-19 patients. Further large-scale, well-designed research and international cooperation are still warranted in clinical evaluations of moxibustion.

Graphical abstract: http://links.lww.com/AHM/A35.

艾灸已广泛应用于新冠肺炎的预防和治疗。然而,目前还没有对艾灸治疗新冠肺炎的主题和临床发现进行系统综述。我们进行了这项范围界定审查,以系统地总结和分析已发表文章的主题和发现,并概述艾灸治疗COVID-19的当前知识和实践。方法:从成立到2022年4月,检索PubMed、Embase、Cochrane图书馆、Web of Science、中国国家知识基础设施、SinoMed、万方数据和VIP数据库。相关数据通过条形图、结构化表格和图表以及描述性统计和分析呈现。本范围审查基于PRISMA ScR检查表进行。结果:共审查了76篇文章:47篇综述、19项临床研究、7项系统综述(均为方案)和3项指南。所有研究均由中国研究人员进行,并于2020年1月1日至2022年3月14日发表。艾灸预防和治疗轻度或中度新冠肺炎的可行性是基于治疗机制和有效性的共识。最常用的方法是悬灸和温和灸,最常用或推荐的穴位是ST36、CV8、CV6、CV4、CV12、GV14、BL13、LI4、ST25和LR3,艾灸在改善新冠肺炎患者的轻度或中度症状方面显著有效。在艾灸的临床评估方面,仍需要进一步大规模、精心设计的研究和国际合作。图形摘要:http://links.lww.com/AHM/A35.
{"title":"Moxibustion for COVID-19: a systematic scoping review.","authors":"Meng Xia, Bo Pang, Shaowei Yi, Xinjue Shan, Shizhe Deng, Yinan Qin, Tao Jiang, Hai Lu","doi":"10.1097/HM9.0000000000000044","DOIUrl":"10.1097/HM9.0000000000000044","url":null,"abstract":"<p><p>Moxibustion has been widely used in the prevention and treatment of COVID-19. However, there is no systematic review of current topics and clinical findings on moxibustion for COVID-19. We conducted this scoping review to systematically summarize and analyze the themes and findings of published articles, and to provide an overview of current knowledge and practice of moxibustion for COVID-19.</p><p><strong>Methods: </strong>PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, SinoMed, Wan Fang Data, and VIP databases were searched from inception until April 2022. The relevant data were presented through bar graphs, structured tables, and figures along with descriptive statistics and analysis. This scoping review was conducted based on the PRISMA-ScR Checklist.</p><p><strong>Results: </strong>A total of 76 articles were reviewed: 47 reviews, 19 clinical research studies, seven systematic reviews (all were protocols), and three guidelines. All the studies were conducted by Chinese researchers and published from January 1, 2020 to March 14, 2022. The feasibility of moxibustion in the prevention and treatment of mild or moderate COVID-19 is based on the consensus of therapeutic mechanisms and effectiveness. The most adopted approach was the suspended and gentle moxibustion, and the most frequently applied or recommended acupoints were found to be ST36, CV8, CV6, CV4, CV12, GV14, BL13, LI4, ST25, and LR3.</p><p><strong>Conclusions: </strong>As a convenient and safe traditional Chinese medicine (TCM) therapy with its specific feature, moxibustion has been significantly effective at ameliorating mild or moderate symptoms among COVID-19 patients. Further large-scale, well-designed research and international cooperation are still warranted in clinical evaluations of moxibustion.</p><p><strong>Graphical abstract: </strong>http://links.lww.com/AHM/A35.</p>","PeriodicalId":93856,"journal":{"name":"Acupuncture and herbal medicine","volume":"2 3","pages":"162-171"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9d/aa/hm9-2-162.PMC9746254.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41160185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-line spectroscopy combined with multivariate analysis methods for endpoint determination in column chromatographic adsorption processes for herbal medicine 中药材柱层析吸附过程中终点确定的多变量分析方法
Pub Date : 2022-08-22 DOI: 10.1097/HM9.0000000000000035
Cheng Jiang, Hai-bin Qu
Objective: In a chromatographic cycle, the adsorption process is a critical unit operation that has a significant impact on downstream processes and, ultimately, the quality of the final products. The development of a rapid method to determine the endpoints of adsorption processes in a large-scale manufacturing is of substantial importance for herbal medicine (HM) manufacturers. Methods: In this study, the adsorption of saponins on a macroporous resin column chromatograph, a critical unit operation in Panax notoginseng (Burkill) F.H.Chen injection manufacturing, was considered as an example. The evaluation results of in-line ultraviolet and visible spectra combined with various multivariate analysis methods, including the moving block standard deviation (MBSD), difference between the moving block average and the target spectrum (DMBA-TS), soft-independent modeling of class analogy (SIMCA), and partial least-squares discriminant analysis (PLS-DA), were compared. Results: MBSD was unsuitable for adsorption processes. The relative standard errors of prediction between the predicted and experimental endpoints were 13.2%, 4.67%, and 5.71% using DMBA-TS, SIMCA, and PLS-DA, respectively. Conclusions: Among the considered analysis methods, SIMCA and PLS-DA were more effective for endpoint determination. The results of this study provide a more comprehensive overview of the effectiveness of various multivariate analysis methods to facilitate the selection of the most suitable method. This study was also conducive to address the issues of the in-line detection of adsorption endpoints to guide practical HM manufacturing. Graphical abstract: http://links.lww.com/AHM/A23
目的:在色谱循环中,吸附过程是一个关键的单元操作,它对下游工艺产生重大影响,并最终影响最终产品的质量。开发一种快速确定大规模生产中吸附过程终点的方法对草药(HM)制造商具有重要意义。方法:以大孔树脂柱色谱仪吸附三七皂苷为例,对三七注射液生产中的关键工序进行了研究。结合移动块标准差(MBSD)、移动块平均值与目标光谱之差(DMBA-TS)、类类比软独立建模(SIMCA)和偏最小二乘判别分析(PLS-DA)等多种多元分析方法,对在线紫外和可见光谱评价结果进行比较。结果:MBSD不适用于吸附工艺。DMBA-TS、SIMCA和PLS-DA预测终点与实验终点的相对标准误差分别为13.2%、4.67%和5.71%。结论:在所考虑的分析方法中,SIMCA和PLS-DA对终点的确定更为有效。本研究的结果对各种多变量分析方法的有效性提供了更全面的概述,以便于选择最合适的方法。该研究也有助于解决吸附端点的在线检测问题,以指导实际的HM制造。图形摘要:http://links.lww.com/AHM/A23
{"title":"In-line spectroscopy combined with multivariate analysis methods for endpoint determination in column chromatographic adsorption processes for herbal medicine","authors":"Cheng Jiang, Hai-bin Qu","doi":"10.1097/HM9.0000000000000035","DOIUrl":"https://doi.org/10.1097/HM9.0000000000000035","url":null,"abstract":"Objective: In a chromatographic cycle, the adsorption process is a critical unit operation that has a significant impact on downstream processes and, ultimately, the quality of the final products. The development of a rapid method to determine the endpoints of adsorption processes in a large-scale manufacturing is of substantial importance for herbal medicine (HM) manufacturers. Methods: In this study, the adsorption of saponins on a macroporous resin column chromatograph, a critical unit operation in Panax notoginseng (Burkill) F.H.Chen injection manufacturing, was considered as an example. The evaluation results of in-line ultraviolet and visible spectra combined with various multivariate analysis methods, including the moving block standard deviation (MBSD), difference between the moving block average and the target spectrum (DMBA-TS), soft-independent modeling of class analogy (SIMCA), and partial least-squares discriminant analysis (PLS-DA), were compared. Results: MBSD was unsuitable for adsorption processes. The relative standard errors of prediction between the predicted and experimental endpoints were 13.2%, 4.67%, and 5.71% using DMBA-TS, SIMCA, and PLS-DA, respectively. Conclusions: Among the considered analysis methods, SIMCA and PLS-DA were more effective for endpoint determination. The results of this study provide a more comprehensive overview of the effectiveness of various multivariate analysis methods to facilitate the selection of the most suitable method. This study was also conducive to address the issues of the in-line detection of adsorption endpoints to guide practical HM manufacturing. Graphical abstract: http://links.lww.com/AHM/A23","PeriodicalId":93856,"journal":{"name":"Acupuncture and herbal medicine","volume":"70 1","pages":"253 - 260"},"PeriodicalIF":0.0,"publicationDate":"2022-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75336209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Anti-fatigue effect from Ginseng Radix et Rhizoma: a suggestive and promising treatment for long COVID. 人参的抗疲劳作用:一种治疗长期新冠肺炎的新方法。
Pub Date : 2022-06-01 Epub Date: 2022-07-08 DOI: 10.1097/HM9.0000000000000033
Xiangda Zhou, Keying Zhang, Lanbo Liu, Qianru Zhao, Ming Huang, Rui Shao, Yanyan Wang, Bin Qu, Yu Wang

Two years after the coronavirus disease 2019 (COVID-19) outbreak, an increasing number of patients continue to suffer from long COVID (LC), persistent symptoms, and/or delayed or long-term complications beyond the initial 4 weeks from the onset of symptoms. Constant fatigue is one of the most common LC symptoms, leading to severely reduced quality of life among patients. Ginseng Radix et Rhizoma-known as the King of Herbs in traditional Chinese medicine-has shown clinical anti-fatigue effects. In this review, we summarize the underlying anti-fatigue mechanisms of Ginseng Radix et Rhizoma extracts and their bioactive compounds, with a special focus on anti-viral, immune remodeling, endocrine system regulation, and metabolism, suggesting that Ginseng Radix et Rhizoma is a potentially promising treatment for LC, especially in regard to targeting fatigue.

2019冠状病毒病(新冠肺炎)爆发两年后,越来越多的患者继续遭受长期COVID(LC)、持续症状和/或延迟或长期并发症,超过最初的4 症状出现后数周。持续疲劳是LC最常见的症状之一,导致患者的生活质量严重降低。人参被誉为中药之王,具有良好的临床抗疲劳作用。在这篇综述中,我们总结了人参提取物及其生物活性化合物的潜在抗疲劳机制,特别是抗病毒、免疫重塑、内分泌系统调节和代谢,表明人参是一种潜在的治疗LC的药物,尤其是在靶向疲劳方面。
{"title":"Anti-fatigue effect from <i>Ginseng Radix et Rhizoma</i>: a suggestive and promising treatment for long COVID.","authors":"Xiangda Zhou, Keying Zhang, Lanbo Liu, Qianru Zhao, Ming Huang, Rui Shao, Yanyan Wang, Bin Qu, Yu Wang","doi":"10.1097/HM9.0000000000000033","DOIUrl":"10.1097/HM9.0000000000000033","url":null,"abstract":"<p><p>Two years after the coronavirus disease 2019 (COVID-19) outbreak, an increasing number of patients continue to suffer from long COVID (LC), persistent symptoms, and/or delayed or long-term complications beyond the initial 4 weeks from the onset of symptoms. Constant fatigue is one of the most common LC symptoms, leading to severely reduced quality of life among patients. <i>Ginseng Radix et Rhizoma</i>-known as the King of Herbs in traditional Chinese medicine-has shown clinical anti-fatigue effects. In this review, we summarize the underlying anti-fatigue mechanisms of <i>Ginseng Radix et Rhizoma</i> extracts and their bioactive compounds, with a special focus on anti-viral, immune remodeling, endocrine system regulation, and metabolism, suggesting that <i>Ginseng Radix et Rhizoma</i> is a potentially promising treatment for LC, especially in regard to targeting fatigue.</p>","PeriodicalId":93856,"journal":{"name":"Acupuncture and herbal medicine","volume":"2 2","pages":"69-77"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c0/ec/hm9-2-69.PMC9407182.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41157037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acupuncture and moxibustion treating lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis 针灸治疗良性前列腺增生引起的下尿路症状:系统综述和网络荟萃分析
Pub Date : 2022-06-01 DOI: 10.1097/HM9.0000000000000029
Zhe Chen, Tao Jiang, Yingying Peng, Xiaoyu Qiang, Fengwen Yang, Haiyin Hu, Chunxiang Liu, Myeong Soo Lee
Abstract Objective: Lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) affect the quality of life of elderly individuals. Acupuncture and moxibustion are used in the clinic in China for improving LUTS symptoms due to BPH. However, there is no evidence to suggest which is the best option. We compared the efficacy of acupuncture and moxibustion to provide evidence for clinical decision-making. Methods: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wan Fang Data, and VIP databases were searched from inception to July 2020 to identify the randomized controlled trials (RCTs) of acupuncture and moxibustion for LUTS due to BPH. Two researchers filtered studies and extracted the information independently. This study conducted a network meta-analysis using the Bayesian random method. The interventions ranking was evaluated using the surface under the cumulative ranking curve (SUCRA). Results: We finally included 40 studies comprising 10 treating therapies and 3655 patients with LUTS caused by BPH. In terms of the International Prostate Symptom Score, maximum urinary flow rate, and quality of life, electroacupuncture (EA) (MD = −3.6, 95% credible interval [CrI] [−5.5, −1.8], very low certainty of evidence; MD = 2.2, 95% CrI [1.1, 3.3], low certainty of evidence; MD = −1.3, 95% CrI [−2.2, −0.43], very low certainty of evidence) may be consistently the optimal treatment compared with other interventions, with SUCRA values of 84%, 81%, and 89%, respectively. Conclusions: Of all treatments, EA may have the best efficacy with fewer adverse events for LUTS due to BPH. The quality of evidence supporting this result is low to very low certainty of the evidence due to limitations of primary studies; thus, more high-quality RCTs are needed for further evidence.
摘要目的:良性前列腺增生(BPH)引起的下尿路症状(LUTS)影响老年人的生活质量。针灸在中国临床上用于改善前列腺增生引起的LUTS症状。然而,没有证据表明哪一个是最好的选择。我们比较针刺和艾灸的疗效,为临床决策提供依据。方法:检索PubMed、Embase、Cochrane图书馆、Web of Science、中国国家知识基础设施、万方数据和VIP数据库,检索自建库至2020年7月的针灸治疗BPH合并LUTS的随机对照试验(rct)。两名研究人员对研究进行筛选,并独立提取信息。本研究采用贝叶斯随机方法进行网络元分析。采用累积排序曲线下曲面(SUCRA)评价干预措施的排序。结果:我们最终纳入了40项研究,包括10种治疗方法和3655例由BPH引起的LUTS患者。在国际前列腺症状评分、最大尿流率和生活质量方面,电针(EA) (MD =−3.6,95%可信区间[CrI][−5.5,−1.8],证据确定性非常低;MD = 2.2, 95% CrI[1.1, 3.3],证据确定性低;MD = - 1.3, 95% CrI[- 2.2, - 0.43],证据确定性极低)与其他干预措施相比,可能始终是最佳治疗方法,SUCRA值分别为84%,81%和89%。结论:在所有治疗方法中,EA可能对BPH引起的LUTS疗效最好,不良事件较少。由于初步研究的局限性,支持这一结果的证据质量很低,证据的确定性很低;因此,需要更多高质量的随机对照试验来获得进一步的证据。
{"title":"Acupuncture and moxibustion treating lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis","authors":"Zhe Chen, Tao Jiang, Yingying Peng, Xiaoyu Qiang, Fengwen Yang, Haiyin Hu, Chunxiang Liu, Myeong Soo Lee","doi":"10.1097/HM9.0000000000000029","DOIUrl":"https://doi.org/10.1097/HM9.0000000000000029","url":null,"abstract":"Abstract Objective: Lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) affect the quality of life of elderly individuals. Acupuncture and moxibustion are used in the clinic in China for improving LUTS symptoms due to BPH. However, there is no evidence to suggest which is the best option. We compared the efficacy of acupuncture and moxibustion to provide evidence for clinical decision-making. Methods: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wan Fang Data, and VIP databases were searched from inception to July 2020 to identify the randomized controlled trials (RCTs) of acupuncture and moxibustion for LUTS due to BPH. Two researchers filtered studies and extracted the information independently. This study conducted a network meta-analysis using the Bayesian random method. The interventions ranking was evaluated using the surface under the cumulative ranking curve (SUCRA). Results: We finally included 40 studies comprising 10 treating therapies and 3655 patients with LUTS caused by BPH. In terms of the International Prostate Symptom Score, maximum urinary flow rate, and quality of life, electroacupuncture (EA) (MD = −3.6, 95% credible interval [CrI] [−5.5, −1.8], very low certainty of evidence; MD = 2.2, 95% CrI [1.1, 3.3], low certainty of evidence; MD = −1.3, 95% CrI [−2.2, −0.43], very low certainty of evidence) may be consistently the optimal treatment compared with other interventions, with SUCRA values of 84%, 81%, and 89%, respectively. Conclusions: Of all treatments, EA may have the best efficacy with fewer adverse events for LUTS due to BPH. The quality of evidence supporting this result is low to very low certainty of the evidence due to limitations of primary studies; thus, more high-quality RCTs are needed for further evidence.","PeriodicalId":93856,"journal":{"name":"Acupuncture and herbal medicine","volume":"7 1","pages":"84 - 90"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85262436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Acupuncture and herbal medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1